Cyclerion Therapeutics, Inc. Common Stock
CYCN Real Time Price USDRecent trades of CYCN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CYCN's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
CYCN Revenue by Segment or Geography
New patents grants
-
Patent Title: Processes for preparation of soluble guanylate cyclase stimulators Mar. 11, 2025
-
Patent Title: Processes and intermediates for the preparation of soluble guanylate cyclase stimulators Jul. 09, 2024
-
Patent Title: Processes for preparation of soluble guanylate cyclase stimulators Dec. 05, 2023
-
Patent Title: Process for preparation of soluble guanylate cyclase stimulators Oct. 03, 2023
-
Patent Title: Sgc stimulators Aug. 22, 2023
-
Patent Title: Processes and intermediates for the preparation of soluble guanylate cyclase stimulators Jul. 25, 2023
-
Patent Title: Treatment of cns diseases with sgc stimulators Jul. 04, 2023
-
Patent Title: Solid forms of an sgc stimulator Feb. 07, 2023
-
Patent Title: Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1h-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sgc stimulators Oct. 11, 2022
-
Patent Title: Process for preparing soluble guanylate cyclase stimulators Oct. 11, 2022
-
Patent Title: Treatment of metabolic syndrome with an sgc stimulator Jul. 19, 2022
-
Patent Title: Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash) Jun. 14, 2022
-
Patent Title: Processes for preparation of soluble guanylate cyclase stimulators May. 03, 2022
-
Patent Title: Processes and intermediates for the preparation of soluble guanylate cyclase stimulators Mar. 15, 2022
-
Patent Title: Sgc stimulators Dec. 28, 2021
-
Patent Title: Sgc stimulators Nov. 23, 2021
-
Patent Title: Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulators Feb. 23, 2021
-
Patent Title: Solid forms of an sgc stimulator Jan. 12, 2021
-
Patent Title: Sgc stimulators Dec. 08, 2020
-
Patent Title: Sgc stimulators Nov. 24, 2020
-
Patent Title: Sgc stimulators May. 05, 2020
-
Patent Title: Sgc stimulators Dec. 31, 2019
-
Patent Title: Sgc stimulators Nov. 12, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CYCN
Number of mentions of CYCN in WallStreetBets Daily Discussion
Recent picks made for CYCN stock on CNBC
ETFs with the largest estimated holdings in CYCN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CYCN stock a Buy, Sell, or Hold?
- What is the price target for $CYCN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CYCN stock?
- Who owns the most shares of $CYCN stock?
- What funds own $CYCN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CYCN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.